Genfit S.A. (EPA:GNFT)

Market Cap	184.50M
Revenue (ttm)	80.47M
Net Income (ttm)	22.27M
Shares Out	49.87M
EPS (ttm)	0.44
PE Ratio	8.47
Forward PE	78.56
Dividend	n/a
Ex-Dividend Date	n/a

Volume	122,668
Average Volume	242,206
Open	3.660
Previous Close	3.650
Day's Range	3.650 - 3.775
52-Week Range	3.025 - 5.860
Beta	1.08
RSI	53.94
Earnings Date	Apr 24, 2025

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 159
• Stock Exchange: Euronext Paris
• Ticker Symbol: GNFT

Financial Performance

In 2023, Genfit's revenue was 34.48 million, an increase of 31.38% compared to the previous year's 26.25 million. Losses were -28.89 million, 21.8% more than in 2022.